ADH1A and neoplasm: Notably, previous studies have demonstrated the ability of the N‐cadherin antagonist peptide ADH‐1 to increase EC monolayer permeability in vitro, and rapidly enhance tumor blood vessel permeability to albumin‐bound Evans blue dye in pre‐clinical models of melanoma.